Additional markers were included in the design for compatibility with consortium-developed arrays and most recent findings (Table 1). The array contains: 2271 markers from the candidate gene/pathway arrays developed and used by the Pharmacogenetics of Nicotine Addiction Treatment (PNAT) research program [31, 37]; 3091 markers from a lung cancer meta-GWAS [50]; 1200 markers related to psychiatric comorbidities from the Psychiatric Genetics Consortium [51]; and 7956 and 2247 markers for pulmonary and cardiovascular phenotypes respectively from the UK Biobank Axiom Array [52].
